3 assets in Kidney Wilms Tumor

Therapeutic assets addressing Kidney Wilms Tumor, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- Kidney Wilms Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Cabozantinib Kidney Wilms Tumor	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Kidney Wilms Tumor	National Cancer Institute (NCI)	P2	CCC (53)